Literature DB >> 4829991

Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets.

S H Wan, P J Pentikainen, D L Azarnoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4829991     DOI： 10.1002/jps.2600630512

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  9 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

Review 2.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

3.  Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Lizanne de Kock; Sherwin K B Sy; Bernd Rosenkranz; Andreas H Diacon; Kim Prescott; Kenneth R Hernandez; Mingming Yu; Hartmut Derendorf; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

4.  Evaluation of para-Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro.

Authors:  M Masud Parvez; Ho Jung Shin; Jin Ah Jung; Jae-Gook Shin
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

5.  Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).

Authors:  Pooja V Hegde; Michael D Howe; Matthew D Zimmerman; Helena I M Boshoff; Sachin Sharma; Brianna Remache; Ziyi Jia; Yan Pan; Anthony D Baughn; Veronique Dartois; Courtney C Aldrich
Journal:  Eur J Med Chem       Date:  2022-02-19       Impact factor: 6.514

6.  Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.

Authors:  Anneke C Hesseling; Paolo Denti; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Maxwell Chirehwa; Jana L Winckler; Jun Mao; Heather R Draper; Lubbe Wiesner; Jennifer Norman; Helen McIlleron; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2022-05-04       Impact factor: 5.938

7.  Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate.

Authors:  Jin Soo Shin; Keun Bon Ku; Yejin Jang; Yi-Seul Yoon; Daeho Shin; Oh Seung Kwon; Yun Young Go; Seong Soon Kim; Myoung Ae Bae; Meehyein Kim
Journal:  J Microbiol       Date:  2017-12-07       Impact factor: 3.422

8.  Improved specificity of the PABA test with p-aminosalicylic acid (PAS).

Authors:  F J Hoek; F A van den Bergh; J T Klein Elhorst; J L Meijer; E Timmer; G N Tytgat
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

Review 9.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.